[
    [
        {
            "time": "",
            "original_text": "白云山(00874)：奇星药业收到有关喉康散等3个药品的《药品再注册批件》",
            "features": {
                "keywords": [
                    "白云山",
                    "奇星药业",
                    "喉康散",
                    "药品再注册批件"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "白云山(00874)：奇星药业收到有关喉康散等3个药品的《药品再注册批件》",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "白云山(600332.SH)：奇星药业获3个药品再注册批件",
            "features": {
                "keywords": [
                    "白云山",
                    "奇星药业",
                    "药品再注册批件"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "白云山(600332.SH)：奇星药业获3个药品再注册批件",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "白云山(00874.HK)子公司收到药品再注册批件",
            "features": {
                "keywords": [
                    "白云山",
                    "子公司",
                    "药品再注册批件"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "白云山(00874.HK)子公司收到药品再注册批件",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "一个月净流出1000亿，白马股摇摇欲坠，外资底何时到来",
            "features": {
                "keywords": [
                    "净流出",
                    "白马股",
                    "外资"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "一个月净流出1000亿，白马股摇摇欲坠，外资底何时到来",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "新冠用药产业链备受关注 磷酸氯喹或法匹拉韦上市公司哪家强？",
            "features": {
                "keywords": [
                    "新冠用药",
                    "产业链",
                    "磷酸氯喹",
                    "法匹拉韦"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "新冠用药产业链备受关注 磷酸氯喹或法匹拉韦上市公司哪家强？",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]